{"nctId":"NCT00033631","briefTitle":"Radiation Therapy in Treating Patients With Stage II Prostate Cancer","startDateStruct":{"date":"2002-03"},"conditions":["Prostate Cancer"],"count":1534,"armGroups":[{"label":"70.2 Gy","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: 70.2 Gy 3D-CRT/IMRT"]},{"label":"79.2 Gy","type":"EXPERIMENTAL","interventionNames":["Radiation: 79.2 Gy 3D-CRT/IMRT"]}],"interventions":[{"name":"70.2 Gy 3D-CRT/IMRT","otherNames":["3D conformal radiation therapy","intensity modulated radiation therapy"]},{"name":"79.2 Gy 3D-CRT/IMRT","otherNames":["3D conformal radiation therapy","intensity modulated radiation therapy"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the prostate\n\n  * Clinical stage T1b-T2b\n* Meets one of the following criteria:\n\n  * Gleason score 2-6 AND prostate-specific antigen (PSA) â‰¥ 10 ng/mL but \\< 20 ng/mL\n  * Gleason score 7 AND PSA \\< 15 ng/mL\n* No regional lymph node involvement\n* No distant metastases\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Any age\n\nPerformance status:\n\n* Zubrod 0-1\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nOther:\n\n* No other invasive malignancy within the past 5 years except localized basal cell or squamous cell skin cancer\n* No other major medical or psychiatric illness that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* No prior cytotoxic chemotherapy\n* No concurrent cytotoxic chemotherapy\n\nEndocrine therapy:\n\n* At least 3 months since prior finasteride\n* No other prior hormonal therapy, including:\n\n  * Luteinizing hormone-releasing hormone agonists (e.g., goserelin or leuprolide)\n  * Antiandrogens (e.g., flutamide or bicalutamide)\n  * Estrogens (e.g., diethylstilbestrol)\n* No concurrent (neoadjuvant or adjuvant) hormonal therapy\n\nRadiotherapy:\n\n* No prior pelvic irradiation or brachytherapy\n\nSurgery:\n\n* No prior radical surgery (prostatectomy) or cryosurgery for prostate cancer\n* No prior surgical castration (bilateral orchiectomy)\n\nOther:\n\n* At least 3 months since prior finasteride or phytoestrogen preparation (PC-SPES)","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier Method. Patients last know to be alive are censored at date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.5","spread":null},{"groupId":"OG001","value":"88.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Prostate-specific Antigen (PSA) Failure by American Society for Therapeutic Radiology and Oncology (ASTRO) Definition","description":"Failure is defined as having 3 consecutive elevations of post-treatment PSA or starting hormones after one or more elevations in post-treatment PSA but before three consecutive elevations were documented. The failure day date was the midpoint between last non-rising PSA and first PSA rise. Failure rates are estimated by the cumulative incidence method. Patients last known to be alive are censored at date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Specific Survival","description":"Survival time is defined as time from randomization to the date of death due to prostate cancer and is estimated by the cumulative incidence method. Patients last know to be alive are censored at date of last contact. Death due to prostate cancer was defined as primary cause of death certified as due to prostate cancer, or death in association with any of the following conditions: Further clinical tumor progression occurring after initiation of salvage anti-tumor therapy, a rise (that exceeds 1.0 ng/ml) in the serum PSA level on at least two consecutive occasions that occurred during or after salvage androgen suppression therapy, or disease progression in the absence of any anti-tumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Progression","description":"Failure time is defined as time from randomization to the date of progression (increase in palpable abnormality), failure of regression of the palpable tumor by two years, and redevelopment of a palpable abnormality after complete disappearance of previous abnormalities. Failure rates are estimated by the cumulative incidence method. Patients last know to be alive are censored at date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Metastases","description":"Failure time is defined as time from randomization to the date of documented regional nodal recurrence or development of distant disease. Failure rates are estimated by the cumulative incidence method. Patients last know to be alive are censored at date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Grade 2 or Greater Genitourinary or Gastrointestinal Toxicity","description":"Rate of acute 2+ grade genitourinary(GU)/gastrointestinal(GI) toxicity graded by Common Toxicity Criteria (CTC) version 2.0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"21.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Erectile Disfuction at 12 Months","description":"The International Index of Erectile Function Questionnaire (IIEF) is the primary measure for erectile function (ED). IIEF question number 1 (\"How often were you able to get an erection during sexual activity?\") is scored from: none/almost never (response 0-1) or \\< half the time (response 2-3) to most times/almost always/always (response 4-5). A response of 0 to 3 on question number 1 of the IIEF is considered erectile dysfunction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.06","spread":null},{"groupId":"OG001","value":"49.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improved, Stable, and Declined Spitzer Quality of Life Index (SQLI) at 12 Months","description":"The SQLI measures quality of life for patients with cancer and other chronic diseases. Possible scores range from 0 to 10, with higher scores indicating a better outcome. Change from Baseline is defined as 12 month SQLI - baseline SQLI and is classified as follows:\n\nImprovement: when change \\>= to the standard error of measurement with reliability quotient of 0.5 (SEM); Stable: when -SEM \\< change \\< SEM; Declined: when change \\<= SEM.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"91","spread":null}]},{"measurements":[{"groupId":"OG000","value":"366","spread":null},{"groupId":"OG001","value":"331","spread":null}]},{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality Adjusted Survival by SQLI","description":null,"classes":[]},{"type":"SECONDARY","title":"Tumor Control Probability","description":null,"classes":[]},{"type":"SECONDARY","title":"Normal Tissue Complication Probability","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":744},"commonTop":["Impotence","Urinary frequency","Urinary incontinence","Late RT Toxicity: Bladder/Other GU: NOS","Late RT Toxicity: Bowel : NOS"]}}}